Schrödinger Reports Third-Quarter 2026 Financial Results, Raises Outlook
Schrödinger reported 17% ACV growth and $24 million in drug discovery revenue, and raised its full-year ACV and drug discovery revenue outlook.
Story updates
09:08:26 PM UTC
SquawkNews
Third Quarter ACV of $45 Million, Representing 17% Growth Increases Full-Year 2026 ACV and Drug Disc
Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended September 30, 2026.“We are very pleased with our third quarter performance, delivering 17% ACV growth, $24 million of drug discovery revenue, and raising our full-year ACV and drug discovery revenue outlook. Our…